Kirk E. Cahill

791 total citations
26 papers, 564 citations indexed

About

Kirk E. Cahill is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Kirk E. Cahill has authored 26 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Hematology and 8 papers in Genetics. Recurrent topics in Kirk E. Cahill's work include Acute Myeloid Leukemia Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Kirk E. Cahill is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Kirk E. Cahill collaborates with scholars based in United States, Australia and Philippines. Kirk E. Cahill's co-authors include Bakhtiar Yamini, Ramin A. Morshed, Giovanna M. Bernal, Ralph R. Weichselbaum, Peter Pytel, Clayton D. Crawley, David J. Voce, Longtao Wu, Nassir M. Mansour and Gustavo Larsen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Kirk E. Cahill

23 papers receiving 557 citations

Peers

Countries citing papers authored by Kirk E. Cahill

Since Specialization

Citations

This map shows the geographic impact of Kirk E. Cahill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk E. Cahill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk E. Cahill more than expected).

Fields of papers citing papers by Kirk E. Cahill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk E. Cahill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk E. Cahill. The network helps show where Kirk E. Cahill may publish in the future.

Co-authorship network of co-authors of Kirk E. Cahill

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk E. Cahill. A scholar is included among the top collaborators of Kirk E. Cahill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk E. Cahill. Kirk E. Cahill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis 2025 ·Blood Cancer Journal ·Yazeed Sawalha, Shayna Sarosiek, (unknown), (unknown), Sudip Thapa, Saurabh Zanwar, Kirk E. Cahill, (unknown), Hiral Shah, Shagun Arora, Georgios Pongas, Allison Winter, Ajay Major, Peter A. Riedell, M. Lia Palomba, Prashant Kapoor, Ariel Grajales‐Cruz, (unknown), Sheeba K. Thomas, Jorge J. Castillo	1
2	A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL 2025 ·Blood Advances ·Kirk E. Cahill, James Godfrey, Chadi Nabhan, Justin Kline, Peter A. Riedell, Kenneth S. Cohen, Sunil Narula, Theodore Karrison, (unknown), Reem Karmali, Parameswaran Venugopal, (unknown), Aaron P. Rapoport, Seung‐Tae Lee, Jennie Y. Law, Paul A. S. Fishkin, Iris Isufi, Mario R. Velasco, Lynne Kaminer, Sonali M. Smith	0
3	Hematology/oncology clinical investigator training: Is current model of education adequate? 2024 ·Journal of Clinical Oncology ·Ardaman Shergill, Kirk E. Cahill, Ajay Major, Anand Patel, Kenneth S. Cohen, Peter H. O’Donnell	0
4	Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy 2023 ·Advanced Science ·Guanghao Liang, (unknown), Qiancheng You, Kirk E. Cahill, Chuanyuan Chen, (unknown), Noreen Fulton, Wendy Stock, Olatoyosi Odenike, Chuan He, Dali Han	8
5	Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis 2023 ·Blood ·Yazeed Sawalha, Shayna Sarosiek, (unknown), (unknown), (unknown), Saurabh Zanwar, Kirk E. Cahill, (unknown), (unknown), Shagun Arora, Georgios Pongas, Allison Winter, Ajay Major, Peter A. Riedell, Maria Lia Palomba, Prashant Kapoor, Ariel Grajales‐Cruz, Kenneth H. Shain, Sheeba K. Thomas, Jorge J. Castillo	1
6	Focus on Novel Therapies for Older Adults with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes 2021 ·Kirk E. Cahill, Olatoyosi Odenike	1
7	CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma 2021 ·Scientific Reports ·David J. Voce, Giovanna M. Bernal, Kirk E. Cahill, Longtao Wu, Nassir M. Mansour, Clayton D. Crawley, (unknown), Ainhoa Arina, Ralph R. Weichselbaum, Bakhtiar Yamini	16
8	Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies 2021 ·Blood Advances ·Anand Patel, Kirk E. Cahill, Caner Saygin, Olatoyosi Odenike	29
9	Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT). 2021 ·Journal of Clinical Oncology ·Kirk E. Cahill, (unknown), (unknown), (unknown), Satyajit Kosuri, Adam DuVall, Hongtao Liu, Michael R. Bishop, Richard A. Larson, Wendy Stock	3
10	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia 2020 ·Blood Advances ·Kirk E. Cahill, Yasmin Karimi, Theodore Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike	8
11	Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma 2019 ·Cancer Research ·David J. Voce, Giovanna M. Bernal, Longtao Wu, Clayton D. Crawley, Wei Zhang, Nassir M. Mansour, Kirk E. Cahill, (unknown), Abhineet Uppal, David R. Raleigh, Rubén Spretz, Luis Núñez, Gustavo Larsen, Nikolai N. Khodarev, Ralph R. Weichselbaum, Bakhtiar Yamini	78
12	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors 2019 ·Blood ·Kirk E. Cahill, Anand Patel, Hongtao Liu, Sandeep Gurbuxani, Michael J. Thirman, Satyajit Kosuri, Andrew Artz, Richard A. Larson, Wendy Stock, Jeremy Segal, Olatoyosi Odenike	3
13	Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma 2019 ·Leukemia & lymphoma ·Kirk E. Cahill, (unknown), Peter A. Riedell	10
14	A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia 2018 ·Blood ·(unknown), Pritesh Patel, Vaibhav Agrawal, (unknown), Kirk E. Cahill, Irum Khan, Karen Sweiss, Ardaman Shergill, Gregory S. Calip, Wendy Stock, Olatoyosi Odenike, Helmut König, John G. Quigley	0
15	Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide 2015 ·Cancer Research ·Nassir M. Mansour, Giovanna M. Bernal, Longtao Wu, Clayton D. Crawley, Kirk E. Cahill, David J. Voce, Irina V. Balyasnikova, Wei Zhang, Rubén Spretz, Luis Núñez, Gustavo Larsen, Ralph R. Weichselbaum, Bakhtiar Yamini	15
16	Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy 2015 ·Neuro-Oncology ·Kirk E. Cahill, Ramin A. Morshed, Bakhtiar Yamini	109
17	Latissimus Dorsi and Teres Major Transfer With Reverse Shoulder Arthroplasty Restores Active Motion and Reduces Pain for Posterosuperior Cuff Dysfunction 2015 ·Clinical Orthopaedics and Related Research ·Lewis L. Shi, Kirk E. Cahill, Eugene T. Ek, (unknown), Laurence D. Higgins, Jon J.P. Warner	50
18	S-phase-dependent p50/NF-кB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability 2015 ·Cell Cycle ·Clayton D. Crawley, (unknown), Giovanna M. Bernal, (unknown), David J. Voce, Kirk E. Cahill, Andrea Garofalo, David R. Raleigh, Ralph R. Weichselbaum, Bakhtiar Yamini	10
19	Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma 2013 ·Nanomedicine Nanotechnology Biology and Medicine ·Giovanna M. Bernal, Michael J. LaRiviere, Nassir M. Mansour, Peter Pytel, Kirk E. Cahill, David J. Voce, (unknown), Rubén Spretz, U. Welp, Sandra Noriega, Luis Núñez, Gustavo Larsen, Ralph R. Weichselbaum, Bakhtiar Yamini	76
20	ATGAM Versus OKT3 Induction Therapy in Cadaveric Kidney Transplantation: Patient and Graft Survival, CD3 Subset, Infection, and Cost Analysis 1998 ·Transplantation Proceedings ·M. S. A. Kumar, Kirk E. Cahill, Aryavarta M. S. Kumar, (unknown), (unknown), (unknown), Ismail H. Al-Abdullah, David A. Laskow	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact